I'm LongbridgeAI, I can summarize articles.FY2026 saw a major setback with the discontinuation of the TACTI-004 trial and a resulting impairment, but positive clinical data in other programs and a strategic licensing deal with Dr Reddy's supported revenue growth. The company ended the year with A$68.9M in cash and expects a reduced loss in FY2027.Original document: Immutep Ltd [IMM] Annual Report — Aug. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
FY2026 saw a major setback with the discontinuation of the TACTI-004 trial and a resulting impairment, but positive clinical data in other programs and a strategic licensing deal with Dr Reddy's supported revenue growth. The company ended the year with A$68.9M in cash and expects a reduced loss in FY2027.
Original document: Immutep Ltd [IMM] Annual Report — Aug. 30 2026